Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver entities : Novo nordisk a::S save search
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.33 -2.02% -2.06% 11K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 2.1%
H: 0.56%
C: 0.56%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 1.54%
H: 4.55%
C: 3.79%
treatment rare liver
Liver Fibrosis Market to Surge at a CAGR of 15.9% by 2032 | DelveInsight
Published: 2022-09-05 (Crawled : 16:00) - prnewswire.com
SGMT | $4.0 0.76% 0.75% 430K
|
Health Technology
| Email alert
Add to watchlist
ETNB | $9.08 2.25% 2.2% 1M
|
Health Technology
| Email alert
Add to watchlist
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
| Email alert
Add to watchlist
LPCN | $5.33 -2.02% -2.06% 11K
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
| Email alert
Add to watchlist
fibrosis liver market
Insulin Delivery Devices Market to Hit $39,371.8 Million Revenue by 2030, says P&S Intelligence
Published: 2022-03-18 (Crawled : 07:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 2.46%
H: 0.6%
C: 0.41%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.12%
H: 1.93%
C: 0.63%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.24%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.62%
H: 1.07%
C: 0.89%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: -0.35%
H: 5.54%
C: 5.11%
device liver intel insulin
At 9.7% CAGR, Insulin Delivery Devices Market Size to hit USD 33.05 Billion in 2028, Says Brandessence Market Research
Published: 2022-01-03 (Crawled : 12:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
ce mark device research liver insulin
Global $19 Billion Home-Use Insulin Delivery Devices Markets, 2015-2020 & 2021-2030
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.2%
H: 1.62%
C: 1.37%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.45%
H: 2.78%
C: 1.68%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 0.57%
H: 0.63%
C: -0.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 0.29%
H: 3.22%
C: 3.08%
device liver insulin
Transdermal Drug Delivery Market is Growing at a CAGR of 9.8% during the Study Period from 2021 to 2026, Asserts DelveInsight
Published: 2021-12-14 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
|
| O: -1.42%
H: 0.02%
C: 0.02%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.44%
H: 5.82%
C: 1.91%
TRUMY | $16.507 0.79% 34K
|
Manufacturing
|
| O: -1.37%
H: 0.68%
C: 0.37%
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.8%
H: 0.08%
C: -0.43%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.2%
H: 0.66%
C: -0.52%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 2.71%
H: 2.77%
C: 1.21%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -1.63%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: -0.82%
H: 0.38%
C: -2.71%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -5.76%
H: 7.53%
C: 0.47%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: -0.31%
H: 0.7%
C: -0.63%
drug liver growing drug delivery
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
Published: 2021-08-18 (Crawled : 08:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.04%
H: 0.72%
C: -0.91%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.03%
H: 0.28%
C: -1.12%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.26%
H: 1.01%
C: -1.28%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.3%
C: -2.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.17%
H: 1.16%
C: -0.04%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 0.21%
H: 0.12%
C: -2.14%
insulin device liver
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.